Skip to main
ELAN

ELAN Stock Forecast & Price Target

ELAN Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 25%
Buy 50%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Elanco Animal Health demonstrates a robust market position with Simparica Trio maintaining over 50% market share, while the rising trajectory of Credelio Quattro is projected to increase from 12.8% in 2025 to an estimated 16.8% by 2026. Additionally, the company has recorded significant year-over-year growth for its Advantage Family and Seresto products, achieving increases of 33% and 28% respectively in the third quarter of 2025, which reflects a sustained positive sales trend. The strategic acquisitions made by Elanco since its spin-off from Eli Lilly, combined with a diverse portfolio across companion and food animals, underpin a favorable outlook for the company's overall financial performance.

Bears say

Elanco Animal Health faces potential near-term earnings growth risks due to refinancing concerns, particularly in light of rising interest rates exemplified by Dentsply Sirona's recent debt offering at 8.375%. Despite a revenue increase of approximately 50%, the company's EBITDA margin has declined by a couple of hundred basis points, signaling concerns over cost management and profitability. Furthermore, while a $28 million EBITDA outperformance was reported in the second quarter, it raises questions regarding the sustainability of such performance in the context of overall financial health and the imminent risks posed by debt refinancing.

ELAN has been analyzed by 8 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 50% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Elanco Animal Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Elanco Animal Health Inc (ELAN) Forecast

Analysts have given ELAN a Buy based on their latest research and market trends.

According to 8 analysts, ELAN has a Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Elanco Animal Health Inc (ELAN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.